Zydus Pharmaceutical USA, a subsidiary of Ahmedabad-based Cadila Healthcare, has lost a patent infringement suit in the US. Recently, a New Jersey district court ruled in favour of Japan’s Takeda Pharmaceutical Company, which had appealed to the court, saying Zydus’ proposed generic gastric relief drug would unfairly compete with its Prevacid SoluTab.“The court finds Zydus infringed claim 1 of the 994 patent. The court further finds defendants have not established by clear and convincing evidence that claim 1 of the 994 patent is invalid. Consequently, the judgment shall be entered in favor of the plaintiffs,” the verdict said. US district judge Joel A Pisano barred Zydus from manufacturing or selling its proposed drug for the treatment of gastric ulcers until Takeda’s patent number 63,28,994 expired in 2019. Zydus could not be reached for comment.
Takeda had filed a case of patent infringement in response to Zydus’ abbreviated new drug application (ANDA) with the US Food and Drug Administration (US FDA), seeking approval to market and sell a generic version of Takeda’s